Sc Pharmaceuticals scheduled to receive FDA approval for expanded use of FUROSCIX on August 08 2024

Sc Pharmaceuticals manufactures a wearable version of Lasix, used to combat fluid retention, manage kidney failure, and manage congenital heart failure. The FDA has set Saturday, August 10, 2024 as the pdufa deadline to decide whether to expand use of Furoscix to New York State class 4 heart failure patients.

Based on recent timing of press releases for positive developments, the FDA will likely release approval news on Thursday, August 08 2024 afterhours.

If my prediction is correct, the stock will increase 10-15% afterhours following news release, and then go negative on the following trading day when yearly sales guidance is released during conference call, similar to Akebia Therapeutics. The best way to take advantage of this is to buy the stock before news, dump the stock after news release during afterhours trading, and then buy 5 dollar strike put options expiring 08/16/2024 at market open following day.